Back to search
FDAFDA · Food and drugs·Recall number D-0295-2015

MIDAZOLAM HYDROCHLORIDE INJECTION, 5 mg/1 mL, C-IV, For IM or IV Use, 2 mL Vials, Rx only. APP Pharmaceuticals, LLC. Schaumburg, IL 60173. NDC: 63323-412-25.

Published December 17, 2014 · Recall initiated: September 27, 2012

Summary

FDA records drug Class II recall D-0295-2015, published December 17, 2014 and initiated September 27, 2012. Recalling firm: Fresenius Kabi USA, LLC; Status: Terminated; Reported quantity: 101,200 Vials; Lot: Lot 6003827, Exp. Date 04/2015. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.

What to do

Voluntary: Firm initiated · Letter

Get an email if MIDAZOLAM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
MIDAZOLAM
Manufacturer
Fresenius Kabi USA, LLC
Distributor
U.S. Nationwide Including Puerto Rico
UPC
0363323411183
Lot
Lot 6003827, Exp. Date 04/2015
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was MIDAZOLAM HYDROCHLORIDE INJECTION, 5 mg/1 mL, C-IV, For IM or IV Use, 2 mL Vials, Rx only. APP Pharmaceuticals, LLC. Schaumburg, IL 60173. NDC: 63323-412-25. recalled?

Yes. FDA published recall D-0295-2015 on December 17, 2014. Reported hazard: Lack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: MIDAZOLAM. UPC: 0363323411183.